AAPL328.22+3.26 (+1.00%) ▲|ABBV260.89-0.83 (-0.32%) ▼|ABT108.63-1.85 (-1.67%) ▼|ACN194.49+6.81 (+3.63%) ▲|ADBE284.31+4.52 (+1.61%) ▲|AMAT435.58-2.88 (-0.66%) ▼|AMD457.58+0.52 (+0.11%) ▲|AMGN444.03+1.19 (+0.27%) ▲|AMT177.67+4.75 (+2.75%) ▲|AMZN258.45+3.47 (+1.36%) ▲|AVGO354.44-12.80 (-3.49%) ▼|AXP330.27+0.29 (+0.09%) ▲|BA208.90+0.03 (+0.01%) ▲|BAC63.04+0.44 (+0.69%) ▲|BKNG196.53-3.07 (-1.54%) ▼|BLK1,115.05+7.97 (+0.72%) ▲|BMY67.86+0.20 (+0.29%) ▲|BNY163.70+1.66 (+1.02%) ▲|BRK-B507.73+2.49 (+0.49%) ▲|C137.87+3.53 (+2.62%) ▲|CAT796.71+4.43 (+0.56%) ▲|CL90.29+0.19 (+0.21%) ▲|CMCSA26.62-0.19 (-0.70%) ▼|COF219.85+3.25 (+1.50%) ▲|COP136.18-1.02 (-0.74%) ▼|COST928.93+0.45 (+0.05%) ▲|CRM264.64+7.71 (+3.00%) ▲|CSCO109.03-0.43 (-0.39%) ▼|CVS97.77+0.54 (+0.56%) ▲|CVX212.65+0.87 (+0.41%) ▲|DE693.95-4.42 (-0.63%) ▼|DHR208.54-1.37 (-0.65%) ▼|DIS107.62-0.36 (-0.33%) ▼|DUK121.66+1.10 (+0.91%) ▲|EMR149.81+0.83 (+0.55%) ▲|FDX320.65+4.11 (+1.30%) ▲|GD364.06-0.01 (0.00%) ▼|GE332.16+2.66 (+0.81%) ▲|GEV942.92+20.98 (+2.28%) ▲|GILD149.98+0.37 (+0.25%) ▲|GM86.82+1.95 (+2.30%) ▲|GOOG338.90+5.12 (+1.53%) ▲|GOOGL342.31+5.19 (+1.54%) ▲|GS1,034.79+30.37 (+3.02%) ▲|HD318.96+2.78 (+0.88%) ▲|HON207.92+1.85 (+0.90%) ▲|IBM233.68+1.98 (+0.85%) ▲|INTC91.24+1.19 (+1.32%) ▲|INTU347.75+4.81 (+1.40%) ▲|ISRG370.25-1.64 (-0.44%) ▼|JNJ278.23+3.02 (+1.10%) ▲|JPM361.28+5.06 (+1.42%) ▲|KO88.96+0.72 (+0.82%) ▲|LIN483.22-2.63 (-0.54%) ▼|LLY1,159.84-0.25 (-0.02%) ▼|LMT531.82+0.27 (+0.05%) ▲|LOW202.50+2.66 (+1.33%) ▲|LRCX287.79-0.53 (-0.18%) ▼|MA584.13-4.01 (-0.68%) ▼|MCD259.17-1.78 (-0.68%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.77+0.59 (+0.63%) ▲|META612.97+20.12 (+3.39%) ▲|MMM167.92-0.83 (-0.49%) ▼|MO69.87+0.31 (+0.44%) ▲|MRK151.70+0.06 (+0.04%) ▲|MS216.37+4.55 (+2.15%) ▲|MSFT510.21+13.39 (+2.70%) ▲|MU940.98-15.11 (-1.58%) ▼|NEE83.99+0.89 (+1.07%) ▲|NFLX82.32-0.41 (-0.50%) ▼|NKE38.58+0.34 (+0.88%) ▲|NOW143.96+7.24 (+5.30%) ▲|NVDA227.10+2.69 (+1.20%) ▲|ORCL154.63+8.88 (+6.09%) ▲|PEP139.76-0.77 (-0.54%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG147.69+0.05 (+0.03%) ▲|PLTR182.95+13.49 (+7.96%) ▲|PM187.63-0.32 (-0.17%) ▼|QCOM169.26+0.22 (+0.13%) ▲|RTX201.61+0.83 (+0.41%) ▲|SBUX106.14-0.58 (-0.54%) ▼|SCHW110.13+1.89 (+1.75%) ▲|SO89.14+0.83 (+0.94%) ▲|SPG211.31+1.11 (+0.53%) ▲|T26.18+0.23 (+0.87%) ▲|TMO609.78+1.24 (+0.20%) ▲|TMUS188.89+1.59 (+0.85%) ▲|TSLA382.04+25.03 (+7.01%) ▲|TXN253.66-1.14 (-0.45%) ▼|UBER75.81-0.64 (-0.84%) ▼|UNH403.99+4.33 (+1.08%) ▲|UNP291.37+1.64 (+0.57%) ▲|UPS103.30+0.29 (+0.28%) ▲|USB63.55+0.78 (+1.23%) ▲|V377.27-1.14 (-0.30%) ▼|VZ50.74+0.52 (+1.03%) ▲|WFC89.24-0.03 (-0.03%) ▼|WMT109.09+3.00 (+2.83%) ▲|XOM163.58-0.58 (-0.35%) ▼|AAPL328.22+3.26 (+1.00%) ▲|ABBV260.89-0.83 (-0.32%) ▼|ABT108.63-1.85 (-1.67%) ▼|ACN194.49+6.81 (+3.63%) ▲|ADBE284.31+4.52 (+1.61%) ▲|AMAT435.58-2.88 (-0.66%) ▼|AMD457.58+0.52 (+0.11%) ▲|AMGN444.03+1.19 (+0.27%) ▲|AMT177.67+4.75 (+2.75%) ▲|AMZN258.45+3.47 (+1.36%) ▲|AVGO354.44-12.80 (-3.49%) ▼|AXP330.27+0.29 (+0.09%) ▲|BA208.90+0.03 (+0.01%) ▲|BAC63.04+0.44 (+0.69%) ▲|BKNG196.53-3.07 (-1.54%) ▼|BLK1,115.05+7.97 (+0.72%) ▲|BMY67.86+0.20 (+0.29%) ▲|BNY163.70+1.66 (+1.02%) ▲|BRK-B507.73+2.49 (+0.49%) ▲|C137.87+3.53 (+2.62%) ▲|CAT796.71+4.43 (+0.56%) ▲|CL90.29+0.19 (+0.21%) ▲|CMCSA26.62-0.19 (-0.70%) ▼|COF219.85+3.25 (+1.50%) ▲|COP136.18-1.02 (-0.74%) ▼|COST928.93+0.45 (+0.05%) ▲|CRM264.64+7.71 (+3.00%) ▲|CSCO109.03-0.43 (-0.39%) ▼|CVS97.77+0.54 (+0.56%) ▲|CVX212.65+0.87 (+0.41%) ▲|DE693.95-4.42 (-0.63%) ▼|DHR208.54-1.37 (-0.65%) ▼|DIS107.62-0.36 (-0.33%) ▼|DUK121.66+1.10 (+0.91%) ▲|EMR149.81+0.83 (+0.55%) ▲|FDX320.65+4.11 (+1.30%) ▲|GD364.06-0.01 (0.00%) ▼|GE332.16+2.66 (+0.81%) ▲|GEV942.92+20.98 (+2.28%) ▲|GILD149.98+0.37 (+0.25%) ▲|GM86.82+1.95 (+2.30%) ▲|GOOG338.90+5.12 (+1.53%) ▲|GOOGL342.31+5.19 (+1.54%) ▲|GS1,034.79+30.37 (+3.02%) ▲|HD318.96+2.78 (+0.88%) ▲|HON207.92+1.85 (+0.90%) ▲|IBM233.68+1.98 (+0.85%) ▲|INTC91.24+1.19 (+1.32%) ▲|INTU347.75+4.81 (+1.40%) ▲|ISRG370.25-1.64 (-0.44%) ▼|JNJ278.23+3.02 (+1.10%) ▲|JPM361.28+5.06 (+1.42%) ▲|KO88.96+0.72 (+0.82%) ▲|LIN483.22-2.63 (-0.54%) ▼|LLY1,159.84-0.25 (-0.02%) ▼|LMT531.82+0.27 (+0.05%) ▲|LOW202.50+2.66 (+1.33%) ▲|LRCX287.79-0.53 (-0.18%) ▼|MA584.13-4.01 (-0.68%) ▼|MCD259.17-1.78 (-0.68%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.77+0.59 (+0.63%) ▲|META612.97+20.12 (+3.39%) ▲|MMM167.92-0.83 (-0.49%) ▼|MO69.87+0.31 (+0.44%) ▲|MRK151.70+0.06 (+0.04%) ▲|MS216.37+4.55 (+2.15%) ▲|MSFT510.21+13.39 (+2.70%) ▲|MU940.98-15.11 (-1.58%) ▼|NEE83.99+0.89 (+1.07%) ▲|NFLX82.32-0.41 (-0.50%) ▼|NKE38.58+0.34 (+0.88%) ▲|NOW143.96+7.24 (+5.30%) ▲|NVDA227.10+2.69 (+1.20%) ▲|ORCL154.63+8.88 (+6.09%) ▲|PEP139.76-0.77 (-0.54%) ▼|PFE28.81-0.21 (-0.72%) ▼|PG147.69+0.05 (+0.03%) ▲|PLTR182.95+13.49 (+7.96%) ▲|PM187.63-0.32 (-0.17%) ▼|QCOM169.26+0.22 (+0.13%) ▲|RTX201.61+0.83 (+0.41%) ▲|SBUX106.14-0.58 (-0.54%) ▼|SCHW110.13+1.89 (+1.75%) ▲|SO89.14+0.83 (+0.94%) ▲|SPG211.31+1.11 (+0.53%) ▲|T26.18+0.23 (+0.87%) ▲|TMO609.78+1.24 (+0.20%) ▲|TMUS188.89+1.59 (+0.85%) ▲|TSLA382.04+25.03 (+7.01%) ▲|TXN253.66-1.14 (-0.45%) ▼|UBER75.81-0.64 (-0.84%) ▼|UNH403.99+4.33 (+1.08%) ▲|UNP291.37+1.64 (+0.57%) ▲|UPS103.30+0.29 (+0.28%) ▲|USB63.55+0.78 (+1.23%) ▲|V377.27-1.14 (-0.30%) ▼|VZ50.74+0.52 (+1.03%) ▲|WFC89.24-0.03 (-0.03%) ▼|WMT109.09+3.00 (+2.83%) ▲|XOM163.58-0.58 (-0.35%) ▼|
25.1 C
New York
Thursday, September 3, 2026

Tag: access

Alvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®

REYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT16, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) lyophilized vial for intravenous administration.

DL Holdings’ Fourth “Victoria Harbour Night Talk”: The AI Wave: Global Investment & Hong Kong Opportunities

HONG KONG, June 8, 2026 /PRNewswire/ -- The Fourth "Victoria Harbour Night Talk" concluded successfully on June 5 at Cloud 39, The Henderson, Central,...

Arrivia and KrisFlyer Expand Partnership to Launch Cruise Redemptions with Miles

SINGAPORE, June 8, 2026 /PRNewswire/ -- arrivia and KrisFlyer, the lifestyle rewards programme of the Singapore Airlines Group, are elevating member benefits with the...

TGS Acquires Apparition Geoservices to Deliver a Step-Change in Seismic Efficiency and Subsurface Imaging

TGS Acquires Apparition Geoservices to Deliver a Step-Change in Seismic Efficiency and Subsurface Imaging

A New Lease of Life: Stories of Hope, Survivorship and Second Chances with Apollo Hospitals

Cancer changes lives long before it changes medical reports.NEW DELHI , June 8, 2026 /PRNewswire/ -- It disrupts routines, alters plans, and tests families in...

Puri, Wayanad and Goa Emerge as Trending Summer Choices for Indian Families, Agoda Reports

SINGAPORE, June 8, 2026 /PRNewswire/ -- Digital travel platform Agoda has recorded a rise in family accommodation searches for domestic summer travel compared to last...

HTX Launches “Appreciation Program” with Over $10 Million to Reward User Trust

APIA, Samoa, June 8, 2026 /PRNewswire/ -- Amid the rapid iteration of the crypto industry and the constant shifts in market conditions, the relationship...

Anamana Incubator Targets Culturally Native Creators to Diversify Homogenized Micro-Drama Market

AI-native micro-serial platform invests in culture-driven stories made by insiders to differentiate from global ROI-driven legacy platformsSINGAPORE, June 7, 2026 /PRNewswire/ -- Anamana, the...

Sapu Nano Expands International Development of Sapu003 and Appoints Global Clinical Trials (GCT) as Lead CRO for Phase 1b Program

SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for...

GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company

Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas
Transaction Establishes a Large-Scale Pharmaceutical Platform in Japan and Strengthens Commercial Capabilities Across Key Therapeutic Areas

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027
The New Drug Application for LNZ100 in China was submitted September 2025 with approval anticipated in Q1 2027

Australian Retirees Seek Reliable Monthly Income From Global Private Credit as Inflation Bites and TermPlus Targets Up To 8.50%* Per Annum

Sydney, Australia, June 07, 2026 (GLOBE NEWSWIRE) -- With annual inflation at 4.6% in the year to March 2026 and roughly 4.4 million Australians now aged 65 and over, retirees face a sharpening challenge: turning a lifetime of savings into income that keeps pace with the rising cost of groceries, fuel and everyday essentials. The pressure is compounded by longevity, with many Australians spending two or even three decades in retirement, and by a shift in mindset that retirement itself demands. In the accumulation years, investors can ride out market volatility and recover losses over time; in the drawdown phase, with shorter horizons and less capacity to recoup losses, the priority moves to predictable income and preserving purchasing power. To learn more visit https://termplus.com.au/insights-news/news/turning-savings-into-reliable-monthly-income-in-retirement/

He Predicted Gold at $5,000. Now He Says This $2 Stock Could Be Even Bigger.

A former CIA and Pentagon advisor says Trump is weeks away from unlocking the largest untapped mineral deposit in the United States
A former CIA and Pentagon advisor says Trump is weeks away from unlocking the largest untapped mineral deposit in the United States

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

VESALIUS-CV Subgroup Results Show Repatha® Reduces Risk of First Major Cardiovascular Events by 29% in People Living with High-Risk DiabetesNew Real-World Data Highlight Treatment...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAccess